Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor survival.
Shapiro RM, Kim HT, Dulery R, Liney D, Garrity HM, Panaro KM, Au C, Gervais C, Little JS, Ho VT, Cutler CS, Koreth J, Gooptu M, Antin JH, Kelkar AH, Romee R, Wu CJ, Ritz J, Soiffer RJ, Nikiforow S.
Shapiro RM, et al. Among authors: au c.
Blood Adv. 2024 May 15:bloodadvances.2023012418. doi: 10.1182/bloodadvances.2023012418. Online ahead of print.
Blood Adv. 2024.
PMID: 38748871